Pursuit releases promising results from Bluebush Zinc Project


Published 11-OCT-2017 12:56 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Pursuit Minerals (ASX:PUR) has released promising early stage data from the first drill hole of the five hole drill program at its Bluebush Zinc Project in Queensland. The project is located approximately 280 kilometres north-northwest of Mount Isa.

PUR intersected a broad interval of zinc and lead sulphides, returning an intersection of 134 meters grading 0.32 per cent zinc and 0.13 per cent lead from 172 metres. The zinc and lead sulphides intersected in drill hole BB01-17 comprise the thickest intersection of sulphides recorded to date on the Bluebush Project.

Commenting on the results, Pursuit Minerals’ Managing Director Jeremy Read said, “The results from hole BB01-17 are intriguing due to the significant width of zinc and lead sulphides intersected and the bands of higher grade zinc within the overall mineralised package of rocks”.

From a geological perspective, Read said the results from the drill hole confirm that Bluebush is a major SEDEX style zinc-lead system with significant potential.

As a backdrop, The Bluebush Project is one of two key projects Pursuit recently purchased from Teck Australia. Within the Bluebush Basin, which is classified as a second-order sub-basin analogous to the sedimentary basin at the Century Zinc Mine, zinc mineralisation extends over an area of 120 square kilometres.

Bluebush project

The drilling program, which was just concluded with the fifth and final hole had the objective of discovering a focal point to the larger Bluebush zinc mineralisation system. This should provide the necessary information to conduct a more targeted follow up drilling program in 2018 with the ultimate goal of defining a mineral resource.

With this in mind, it would appear that PUR is likely to be a news-flow driven story in the near term, as geochemical results from the other four holes will put the assay results from the first hole into context.

Analysts see substantial upside as exploration continues

With Bluebush being in close proximity to the Century Mine, a prolific zinc producer, Gavin Van Der Wath from EverBlu Research suggested in recent coverage that it is possibly the largest area of zinc mineralisation in Australia.

He noted that the Mt Isa Inlier situated in north-west Queensland contains the largest concentration of zinc deposits on the planet and occupies an area of more than 50,000 square kilometres.

Working in PUR’s favour is the fact that the broader area has been extensively explored in the past, providing the company with a large amount of data. Furthermore, significant infrastructure is in place, including the mothballed Century Mine processing plant, powerline to the Century Mine, a slurry pipeline to the coast, road access and an airstrip.

Also taking into account PUR’s highly prospective Paperbark Project located 25 kilometres south-east of the Century Mine, Van Der Wath has attributed a price target of 88 cents per share to PUR, implying upside of nearly 300 per cent to Wednesday morning’s opening price of 22.5 cents.

Past performance is not necessarily indicative of future results. As part of the due diligence process, clients must consider all factors over and above the past performance of the product. Clients should not engage with a product solely on it past performance.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free